Inhaled antibiotics in cystic fibrosis (CF) and non-CF bronchiectasis

Seminars in Respiratory and Critical Care Medicine

Volumn 36, Issue 2, 2015, Pages 267-286

  Tay, George T P ^a   Reid, David W ^a,b   Bell, Scott C ^a,b  

^a THE PRINCE CHARLES HOSPITAL   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

antibiotics; cystic fibrosis; inhaled; nebulized; non CF bronchiectasis; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZTREONAM; AZTREONAM LYSINE; CIPROFLOXACIN; COLISTIMETHATE; COLISTIN; FOSFOMYCIN; GENTAMICIN; LEVOFLOXACIN; TOBRAMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

AIRWAY; ANTIBIOTIC THERAPY; ARTICLE; BRONCHIECTASIS; CYSTIC FIBROSIS; DISEASE EXACERBATION; ERADICATION THERAPY; HUMAN; LUNG FUNCTION; META ANALYSIS (TOPIC); MICROBIOME; MOLECULAR DIAGNOSIS; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPSIS; CLINICAL TRIAL (TOPIC); COMPLICATION; INHALATIONAL DRUG ADMINISTRATION; LUNG; PATHOGENICITY; PATHOLOGY; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; BRONCHIECTASIS; CLINICAL TRIALS AS TOPIC; CYSTIC FIBROSIS; HUMANS; LUNG; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS;

EID: 84926350436     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0035-1547346     Document Type: Article

References (126)

1. Cole P. J. Inflammation: a two-edged sword-the model of bronchiectasis. Eur J Respir Dis Suppl: 1986; 147 6 15
2. Chalmers J. D., Hill A. T. Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis. Mol Immunol: 2013; 55 1 27 34
3. Gaga M., Bentley A. M., Humbert M., et al. Increases in CD4+ T lymphocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis. Thorax: 1998; 53 8 685 691
4. CFTR project (USA) Available at: www.cftr2.org. Accessed February 23, 2015
5. Chang A. B., Grimwood K., Mulholland E. K., Torzillo P. J.; Working Group on Indigenous Paediatric Respiratory Health. Bronchiectasis in indigenous children in remote Australian communities. Med J Aust: 2002; 177 4 200 204
6. Singleton R., Morris A., Redding G., et al. Bronchiectasis in Alaska Native children: causes and clinical courses. Pediatr Pulmonol: 2000; 29 3 182 187
7. Amitani R., Wilson R., Rutman A., et al. Effects of human neutrophil elastase and Pseudomonas aeruginosa proteinases on human respiratory epithelium. Am J Respir Cell Mol Biol: 1991; 4 1 26 32
8. Fuschillo S., De Felice A., Balzano G. Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms. Eur Respir J: 2008; 31 2 396 406
9. Wojnarowski C., Studnicka M., Kühr J., et al. Determinants of eosinophil cationic protein in nasal lavages in children. Clin Exp Allergy: 1998; 28 3 300 305
10. Hirota N., Martin J. G. Mechanisms of airway remodeling. Chest: 2013; 144 3 1026 1032
11. Ward C., Rydell-Törmänen K., Westergren-Thorsson G., Eriksson L. T., Walters H. Infection and remodelling: a 21st century model of bronchiectasis? Eur Respir J: 2011; 38 4 758 760
12. Colin A. A., Ali-Dinar T. Endobronchial biopsy in childhood. Chest: 2007; 131 6 1626 1627
13. Bedrossian C. W., Greenberg S. D., Singer D. B., Hansen J. J., Rosenberg H. S. The lung in cystic fibrosis. A quantitative study including prevalence of pathologic findings among different age groups. Hum Pathol: 1976; 7 2 195 204
14. Morrissey B. M., Evans S. J. Severe bronchiectasis. Clin Rev Allergy Immunol: 2003; 25 3 233 247
15. Bienvenu T., Sermet-Gaudelus I., Burgel P. R., et al. Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med: 2010; 181 10 1078 1084
16. Gonska T., Choi P., Stephenson A., et al. Role of cystic fibrosis transmembrane conductance regulator in patients with chronic sinopulmonary disease. Chest: 2012; 142 4 996 1004
17. King P. T., Holdsworth S. R., Freezer N. J., Villanueva E., Holmes P. W. Characterisation of the onset and presenting clinical features of adult bronchiectasis. Respir Med: 2006; 100 12 2183 2189
18. Ooi C. Y., Dupuis A., Ellis L., et al. Does extensive genotyping and nasal potential difference testing clarify the diagnosis of cystic fibrosis among patients with single-organ manifestations of cystic fibrosis? Thorax: 2014; 69 3 254 260
19. Pasteur M. C., Helliwell S. M., Houghton S. J., et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med: 2000; 162 4, Pt 1 1277 1284
20. Pignatti P. F., Bombieri C., Marigo C., Benetazzo M., Luisetti M. Increased incidence of cystic fibrosis gene mutations in adults with disseminated bronchiectasis. Hum Mol Genet: 1995; 4 4 635 639
21. Pasteur M. C., Bilton D., Hill A. T.; British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax: 2010; 65 01 i1 i58
22. UK CF Registry Annual Data Report 2011. London, UK © Cystic Fibrosis Trust 2013: 2013
23. Australia C. F. 2012 15th Annual Report from the Cystic Fibrosis Data Registry. Sydney, Australia Cystic Fibrosis Australia: 2013
24. Cystic Fibrosis Foundation Patient Registry 2012 Annual Data Report. Bethesda, Maryland © 2013 Cystic Fibrosis Foundation: 2013
25. Zemanick E. T., Sagel S. D., Harris J. K. The airway microbiome in cystic fibrosis and implications for treatment. Curr Opin Pediatr: 2011; 23 3 319 324
26. Hare K. M., Grimwood K., Leach A. J., et al. Respiratory bacterial pathogens in the nasopharynx and lower airways of Australian indigenous children with bronchiectasis. J Pediatr: 2010; 157 6 1001 1005
27. Kapur N., Grimwood K., Masters I. B., Morris P. S., Chang A. B. Lower airway microbiology and cellularity in children with newly diagnosed non-CF bronchiectasis. Pediatr Pulmonol: 2012; 47 3 300 307
28. Angrill J., Agustí C., de Celis R., et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax: 2002; 57 1 15 19
29. Chan S. L., Chan-Yeung M. M., Ooi G. C., et al. Validation of the Hong Kong Chinese version of the St. George Respiratory Questionnaire in patients with bronchiectasis. Chest: 2002; 122 6 2030 2037
30. Palwatwichai A., Chaoprasong C., Vattanathum A., Wongsa A., Jatakanon A. Clinical, laboratory findings and microbiologic characterization of bronchiectasis in Thai patients. Respirology: 2002; 7 1 63 66
31. Rogers G. B., van der Gast C. J., Cuthbertson L., et al. Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition. Thorax: 2013; 68 8 731 737
32. Tunney M. M., Einarsson G. G., Wei L., et al. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med: 2013; 187 10 1118 1126
33. Rogers G. B., Zain N. M., Bruce K. D., et al. A novel microbiota stratification system predicts future exacerbations in bronchiectasis. Ann Am Thorac Soc: 2014; 11 4 496 503
34. Evans S. A., Turner S. M., Bosch B. J., Hardy C. C., Woodhead M. A. Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa. Eur Respir J: 1996; 9 8 1601 1604
35. Ho P. L., Chan K. N., Ip M. S., et al. The effect of Pseudomonas aeruginosa infection on clinical parameters in steady-state bronchiectasis. Chest: 1998; 114 6 1594 1598
36. Martínez-García M. A., Soler-Cataluña J. J., Perpiñá-Tordera M., Román-Sánchez P., Soriano J. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest: 2007; 132 5 1565 1572
37. Miszkiel K. A., Wells A. U., Rubens M. B., Cole P. J., Hansell D. M. Effects of airway infection by Pseudomonas aeruginosa: a computed tomographic study. Thorax: 1997; 52 3 260 264
38. Wilson C. B., Jones P. W., O'Leary C. J., Hansell D. M., Cole P. J., Wilson R. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J: 1997; 10 8 1754 1760
39. Brodt A. M., Stovold E., Zhang L. Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review. Eur Respir J: 2014; 44 2 382 393
40. Ryan G., Singh M., Dwan K. Inhaled antibiotics for long-term therapy in cystic fibrosis. Cochrane Database Syst Rev: 2011; 3 CD001021
41. Rogers G. B., van der Gast C. J., Serisier D. J. Predominant pathogen competition and core microbiota divergence in chronic airway infection. ISME J: 2015; 9 1 217 225
42. Fodor A. A., Klem E. R., Gilpin D. F., et al. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. PLoS ONE: 2012; 7 9 e45001
43. Smith D. J., Badrick A. C., Zakrzewski M., et al. Pyrosequencing reveals transient cystic fibrosis lung microbiome changes with intravenous antibiotics. Eur Respir J: 2014; 44 4 922 930
44. Mahenthiralingam E. Emerging cystic fibrosis pathogens and the microbiome. Paediatr Respir Rev: 2014; 15 01 13 15
45. Tunney M. M., Field T. R., Moriarty T. F., et al. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med: 2008; 177 9 995 1001
46. Tunney M. M., Klem E. R., Fodor A. A., et al. Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis. Thorax: 2011; 66 7 579 584
47. Jones A. M. Anaerobic bacteria in cystic fibrosis: pathogens or harmless commensals? Thorax: 2011; 66 7 558 559
48. van der Gast C. J., Cuthbertson L., Rogers G. B., et al. Three clinically distinct chronic pediatric airway infections share a common core microbiota. Ann Am Thorac Soc: 2014; 11 7 1039 1048
49. Hoiby N., Bjarnsholt T., Givskov M., Molin S., Ciofu O. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents: 2010; 35 4 322 332
50. Hoiby N., Ciofu O., Bjarnsholt T. Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiol: 2010; 5 11 1663 1674
51. Oggioni M. R., Trappetti C., Kadioglu A., et al. Switch from planktonic to sessile life: a major event in pneumococcal pathogenesis. Mol Microbiol: 2006; 61 5 1196 1210
52. Starner T. D., Zhang N., Kim G., Apicella M. A., McCray P. B. Jr. Haemophilus influenzae forms biofilms on airway epithelia: implications in cystic fibrosis. Am J Respir Crit Care Med: 2006; 174 2 213 220
53. Coakley R. J., Taggart C., Canny G., Greally P., O'Neill S. J., McElvaney N. G. Altered intracellular pH regulation in neutrophils from patients with cystic fibrosis. Am J Physiol Lung Cell Mol Physiol: 2000; 279 1 L66 L74
54. Poulsen J. H., Fischer H., Illek B., Machen T. E. Bicarbonate conductance and pH regulatory capability of cystic fibrosis transmembrane conductance regulator. Proc Natl Acad Sci U S A: 1994; 91 12 5340 5344
55. Moriarty T. F., Elborn J. S., Tunney M. M. Effect of pH on the antimicrobial susceptibility of planktonic and biofilm-grown clinical Pseudomonas aeruginosa isolates. Br J Biomed Sci: 2007; 64 3 101 104
56. Worlitzsch D., Tarran R., Ulrich M., et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest: 2002; 109 3 317 325
57. Field T. R., White A., Elborn J. S., Tunney M. M. Effect of oxygen limitation on the in vitro antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa grown planktonically and as biofilms. Eur J Clin Microbiol Infect Dis: 2005; 24 10 677 687
58. Hill D., Rose B., Pajkos A., et al. Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. J Clin Microbiol: 2005; 43 10 5085 5090
59. Döring G., Flume P., Heijerman H., Elborn J. S.; Consensus Study Group. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros: 2012; 11 6 461 479
60. Amin R., Ratjen F. Emerging drugs for cystic fibrosis. Expert Opin Emerg Drugs: 2014; 19 1 143 155
61. Tullis D. E., Burns J. L., Retsch-Bogart G. Z., et al. Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: a placebo-controlled trial. J Cyst Fibros: 2014; 13 3 296 305
62. Ramsey B. W., Dorkin H. L., Eisenberg J. D., et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med: 1993; 328 24 1740 1746
63. Ramsey B. W., Pepe M. S., Quan J. M., et al. Cystic Fibrosis Inhaled Tobramycin Study Group. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med: 1999; 340 1 23 30
64. Moss R. B. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest: 2002; 121 1 55 63
65. Murphy T. D., Anbar R. D., Lester L. A., et al. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr Pulmonol: 2004; 38 4 314 320
66. Konstan M. W., Geller D. E., Minić P., Brockhaus F., Zhang J., Angyalosi G. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. Pediatr Pulmonol: 2011; 46 3 230 238
67. McCoy K. S., Quittner A. L., Oermann C. M., Gibson R. L., Retsch-Bogart G. Z., Montgomery A. B. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med: 2008; 178 9 921 928
68. Oermann C. M., Retsch-Bogart G. Z., Quittner A. L., et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol: 2010; 45 11 1121 1134
69. Retsch-Bogart G. Z., Quittner A. L., Gibson R. L., et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest: 2009; 135 5 1223 1232
70. Wainwright C. E., Quittner A. L., Geller D. E., et al. Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa. J Cyst Fibros: 2011; 10 4 234 242
71. Jensen T., Pedersen S. S., Garne S., Heilmann C., Hoiby N., Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother: 1987; 19 6 831 838
72. Hodson M. E., Gallagher C. G., Govan J. R. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J: 2002; 20 3 658 664
73. Schuster A., Haliburn C., Döring G., Goldman M. H.; Freedom Study Group. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax: 2013; 68 4 344 350
74. Assael B. M., Pressler T., Bilton D., et al. AZLI Active Comparator Study Group. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. J Cyst Fibros: 2013; 12 2 130 140
75. Hodson M. E., Penketh A. R., Batten J. C. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet: 1981; 2 8256 1137 1139
76. MacLusky I. B., Gold R., Corey M., Levison H. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol: 1989; 7 1 42 48
77. Nolan G., Moivor P., Levison H., Fleming P. C., Corey M., Gold R. Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin. J Pediatr: 1982; 101 4 626 630
78. Wiesemann H. G., Steinkamp G., Ratjen F., et al. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol: 1998; 25 2 88 92
79. Smith A. L., Ramsey B. W., Hedges D. L., et al. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr Pulmonol: 1989; 7 4 265 271
80. Nikolaizik W. H., Trociewicz K., Ratjen F. Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis. Eur Respir J: 2002; 20 1 122 126
81. Alothman G. A., Alsaadi M. M., Ho B. L., et al. Evaluation of bronchial constriction in children with cystic fibrosis after inhaling two different preparations of tobramycin. Chest: 2002; 122 3 930 934
82. Burns J. L., Van Dalfsen J. M., Shawar R. M., et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis: 1999; 179 5 1190 1196
83. Konstan M. W., Flume P. A., Kappler M., et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros: 2011; 10 1 54 61
84. Dietzsch H. J., Gottschalk B., Heyne K., Leupoid W., Wunderlich P. Cystic fibrosis: comparison of two mucolytic drugs for inhalation treatment (acetylcysteine and arginine hydrochloride). Pediatrics: 1975; 55 1 96 100
85. Gibson R. L., Retsch-Bogart G. Z., Oermann C., et al. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pulmonol: 2006; 41 7 656 665
86. Retsch-Bogart G. Z., Burns J. L., Otto K. L., et al. AZLI Phase II Study Group. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr Pulmonol: 2008; 43 1 47 58
87. Jensen T., Koch C., Pedersen S. S., Hoiby N. Aztreonam for cystic fibrosis patients who are hypersensitive to other beta-lactams. Lancet: 1987; 1 8545 1319 1320
88. Day A. J., Williams J., McKeown C., Bruton A., Weller P. H. Evaluation of inhaled colomycin in children with cystic fibrosis. 10th International Cystic Fibrosis Congress; 1988; 106
89. Goss C. H., Bell S. C. Aztreonam for inhalation solution, challenges to drug approval and integration into CF care. J Cyst Fibros: 2013; 12 2 99 101
90. Mogayzel P. J. Jr, Naureckas E. T., Robinson K. A., et al. Pulmonary Clinical Practice Guidelines Committee. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med: 2013; 187 7 680 689
91. Smyth A. R., Bell S. C., Bojcin S., et al. European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. J Cyst Fibros: 2014; 13 01 S23 S42
92. Valerius N. H., Koch C., Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet: 1991; 338 8769 725 726
93. Langton Hewer S. C., Smyth A. R. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev: 2014; 11 CD004197
94. Tiddens H. A., De Boeck K., Clancy J. P., et al. ALPINE study investigators. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study. J Cyst Fibros: 2015; 14 1 111 119
95. Ryan G., Jahnke N., Remmington T. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. Cochrane Database Syst Rev: 2012; 12 CD008319
96. Meers P., Neville M., Malinin V., et al. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother: 2008; 61 4 859 868
97. Clancy J. P., Dupont L., Konstan M. W., et al. Arikace Study Group. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax: 2013; 68 9 818 825
98. Geller D. E., Flume P. A., Griffith D. C., et al. Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. Antimicrob Agents Chemother: 2011; 55 6 2636 2640
99. Geller D. E., Flume P. A., Staab D., Fischer R., Loutit J. S., Conrad D. J.; Mpex 204 Study Group. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med: 2011; 183 11 1510 1516
100. Trapnell B. C., McColley S. A., Kissner D. G., et al. Phase 2 FTI Study Group. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection. Am J Respir Crit Care Med: 2012; 185 2 171 178
101. Grimwood K., Bell S. C., Chang A. B. Antimicrobial treatment of non-cystic fibrosis bronchiectasis. Expert Rev Anti Infect Ther: 2014; 12 10 1277 1296
102. Insmed, Inc TR02-107 trial report. Available from: www.insmed.com/pdf/Pub9%209-13-09.pdf
103. Barker A. F., Couch L., Fiel S. B., et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med: 2000; 162 2 Pt 1 481 485
104. Drobnic M. E., Suñé P., Montoro J. B., Ferrer A., Orriols R. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother: 2005; 39 1 39 44
105. Murray M. P., Govan J. R., Doherty C. J., et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med: 2011; 183 4 491 499
106. Wilson R., Welte T., Polverino E., et al. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J: 2013; 41 5 1107 1115
107. Serisier D. J., Bilton D., De Soyza A., et al. ORBIT-2 investigators. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax: 2013; 68 9 812 817
108. Haworth C. S., Foweraker J. E., Wilkinson P., Kenyon R. F., Bilton D. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med: 2014; 189 8 975 982
109. Barker A. F., O'Donnell A. E., Flume P., et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med: 2014; 2 9 738 749
110. Couch L. A. Treatment With tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa. Chest: 2001; 120 (3, Suppl): 114S 117S
111. Chang A. B., Bell S. C., Torzillo P. J., et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand: TSANZ guidelines. Med J Aust: 2015; 202 1 21 23
112. Woodhead M. New guidelines for the management of adult lower respiratory tract infections. Eur Respir J: 2011; 38 6 1250 1251
113. Bilton D., Henig N., Morrissey B., Gotfried M. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest: 2006; 130 5 1503 1510
114. Daniels T., Mills N., Whitaker P. Nebuliser systems for drug delivery in cystic fibrosis. Paediatr Respir Rev: 2013; 14 2 98 99
115. Dubus J. C., Bassinet L., Chedevergne F., et al. GRAM (Groupe aérosols et mucoviscidose de la Société française de mucoviscidose). [Inhaled treatments in cystic fibrosis: what's new in 2013?]. Rev Mal Respir: 2014; 31 4 336 346
116. Zhou Q. T., Tang P., Leung S. S., Chan J. G., Chan H. K. Emerging inhalation aerosol devices and strategies: where are we headed? Adv Drug Deliv Rev: 2014; 75 3 17
117. Tiddens H. A., Bos A. C., Mouton J. W., Devadason S., Janssens H. M. Inhaled antibiotics: dry or wet? Eur Respir J: 2014; 44 5 1308 1318
118. Uttley L., Tappenden P. Dry powder inhalers in cystic fibrosis: same old drugs but different benefits? Curr Opin Pulm Med: 2014; 20 6 607 612
119. Tappenden P., Harnan S., Uttley L., et al. The cost effectiveness of dry powder antibiotics for the treatment of Pseudomonas aeruginosa in patients with cystic fibrosis. Pharmacoeconomics: 2014; 32 2 159 172
120. Manca M. L., Cassano R., Valenti D., et al. Isoniazid-gelatin conjugate microparticles containing rifampicin for the treatment of tuberculosis. J Pharm Pharmacol: 2013; 65 9 1302 1311
121. Dames P., Gleich B., Flemmer A., et al. Targeted delivery of magnetic aerosol droplets to the lung. Nat Nanotechnol: 2007; 2 8 495 499
122. Plank C. Nanomagnetosols: magnetism opens up new perspectives for targeted aerosol delivery to the lung. Trends Biotechnol: 2008; 26 2 59 63
123. Stokell J. R., Gharaibeh R. Z., Hamp T. J., Zapata M. J., Fodor A. A., Steck T. R. Analysis of Changes in Diversity and Abundance of the Microbial Community in a Cystic Fibrosis Patient over a Multiyear Period. J Clin Microbiol: 2015; 53 1 237 247
124. Sherrard L. J., Tunney M. M., Elborn J. S. Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis. Lancet: 2014; 384 9944 703 713
125. Quittner A. L., Marciel K. K., Salathe M. A., et al. A preliminary quality of life questionnaire-bronchiectasis: a patient-reported outcome measure for bronchiectasis. Chest: 2014; 146 2 437 448
126. Quittner A. L., O'Donnell A. E., Salathe M. A., et al. Quality of Life Questionnaire-Bronchiectasis: final psychometric analyses and determination of minimal important difference scores. Thorax: 2015; 70 1 12 20